These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 9512903)
21. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543 [TBL] [Abstract][Full Text] [Related]
22. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906 [TBL] [Abstract][Full Text] [Related]
24. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha. Yang SC; Owen-Schaub LB; Roth JA; Grimm EA Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of lymphokine-activated killer cell development in young and old healthy humans. Provinciali M; Di Stefano G; Fabris N Nat Immun; 1995; 14(3):134-44. PubMed ID: 8832897 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture. Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989 [TBL] [Abstract][Full Text] [Related]
27. Characterization of lymphokine-activated killer cells from peripheral blood and lymph nodes of non-Hodgkin's lymphoma patients. Nadkarni JJ; Jhaver KG; De AK; Soman CS; Nadkarni KS Neoplasma; 1993; 40(1):15-20. PubMed ID: 8350943 [TBL] [Abstract][Full Text] [Related]
28. Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study. Naume B; Espevik T J Immunol; 1991 Oct; 147(7):2208-14. PubMed ID: 1717551 [TBL] [Abstract][Full Text] [Related]
29. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related]
30. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199 [TBL] [Abstract][Full Text] [Related]
31. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy. Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036 [TBL] [Abstract][Full Text] [Related]
32. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. Alamartine E; Sabido O; Berthoux F Nephrol Dial Transplant; 1994; 9(10):1456-61. PubMed ID: 7529381 [TBL] [Abstract][Full Text] [Related]
33. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor. Heaton KM; Ju G; Morris DK; Delisio K; Bailon P; Grimm EA Cell Immunol; 1993 Mar; 147(1):167-79. PubMed ID: 8462109 [TBL] [Abstract][Full Text] [Related]
34. IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4. Stötter H; Custer MC; Bolton ES; Guedez L; Lotze MT J Immunol; 1991 Jan; 146(1):150-5. PubMed ID: 1670602 [TBL] [Abstract][Full Text] [Related]
35. A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro. Yano Y; Ueda Y; Itoh T; Fuji N; Okugawa K; Naito K; Imura K; Kohara J; Hayashi T; Nakane K; Matsuura Y; Kawai K; Yamagishi H Oncol Rep; 2006 Jul; 16(1):147-52. PubMed ID: 16786138 [TBL] [Abstract][Full Text] [Related]
36. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells. Atzpodien J; Gulati SC Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310 [TBL] [Abstract][Full Text] [Related]
37. Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3. Okuno K; Ohnishi H; Shilayama Y; Hirohata T; Ozaki M; Yasutomi M Mol Biother; 1992 Jun; 4(2):83-6. PubMed ID: 1515099 [TBL] [Abstract][Full Text] [Related]
38. Changes in homing receptor expression on murine lymphokine-activated killer cells during IL-2 exposure. Steen PD; McGregor JR; Lehman CM; Samlowski WE J Immunol; 1989 Dec; 143(12):4324-30. PubMed ID: 2687380 [TBL] [Abstract][Full Text] [Related]
39. Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients. Zerhouni B; Sanhadji K; Kehrli L; Livrozet JM; Touraine JL Thymus; 1997; 24(3):147-56. PubMed ID: 9151380 [TBL] [Abstract][Full Text] [Related]
40. Effect of ASTA-Z 7575 (INN Maphosphamide) on human lymphokine-activated killer cell induction. Singh KP; Gupta RK; Shau H; Ray PK Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):525-38. PubMed ID: 8301017 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]